Amylyx Pharmaceuticals, Inc. (AMLX)

17.68 -0.68 (-3.70%) USD  |  NASDAQ  |  Apr 20, 12:55
More

Amylyx Pharmaceuticals SG&A Expense (Quarterly) : 15.39M for Dec. 31, 2025

SG&A Expense (Quarterly) Chart

View SG&A Expense (Quarterly) for AMLX.
Upgrade now.
Sep '18
Jan '19
May '19
 
285.00
270.00
255.00
240.00
View SG&A Expense (Quarterly) Chart
Start Trial

Historical Data

View Historical Data
Start Trial

SG&A Expense (Quarterly) Range, Past 5 Years

View SG&A Expense (Quarterly) Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

SG&A Expense (Quarterly) Benchmarks

View SG&A Expense (Quarterly) Benchmarks
Start Trial
Disc Medicine, Inc. 20.75M
Cytokinetics, Inc. 91.72M
Ionis Pharmaceuticals, Inc. 130.00M
MediciNova, Inc. 1.554M
Scholar Rock Holding Corp. 45.02M